What is the catalog number for Rifampicin-d3?

The catalog number for Rifampicin-d3 is HY-B0272S.

What sizes are available for Rifampicin-d3?

Rifampicin-d3 is available in the following size(s): 1 mg.

Is Rifampicin-d3 in stock?

Rifampicin-d3 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Rifampicin-d3?

Rifampicin-d3 is manufactured by QuantiMol.

What is the estimated delivery time for Rifampicin-d3?

Estimated delivery time for Rifampicin-d3 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Rifampicin-d3?

The safety data sheet for Rifampicin-d3 is available here: http://file.medchemexpress.com/batch_PDF/HY-B0272S/Rifampicin-d3-SDS-MedChemExpress.pdf.

Rifampicin-d3

Rifampicin-d3 is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities[1][2].

Product Specifications

CAS Number

1262052-36-7

Product Name Alternative

Rifampin-d3; Rifamycin AMP-d3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial; Influenza Virus

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Purity

95.03

Solubility

10 mM in DMSO

Smiles

OC1=C2C3=C4O[C@@](C)(C3=O)O/C=C/[C@H](OC)[C@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(\C)/C(=O)NC(C(O)=C2C(O)=C4C)=C1/C=N/N5CCN(C([2H])([2H])[2H])CC5

Molecular Formula

C43H55D3N4O12

Molecular Weight

825.96

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979; (2) :333-7.|[3]Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55 (4) :528-34. Epub 2005 Mar 2.|[4]Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006; (8) :58-61.|[5]Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6 (2) :169-74.